Feeling like the days of wishing and hoping for a a PR with

New Post Public Reply Private Reply Replies (0) Message Board
petemantx
438
Feeling like the days of wishing and hoping for a a PR with some sort of good news but not a clue as to when it will come are behind us.

We have a better idea of what to expect moving forward. The first and most urgent step now is the mtg with the EMA to get their input so that we can finalize protocol for OM P3. Prior to this meeting no news from IPIX can be expected IMO and that is fine with me.

I expect we get a PR after this mtg has occurred and we get positive feedback from EMA and feel we can incorporate everything required by the FDA/EMA into a P3 as stockholders deserve to be kept somewhat in the loop as to what is progressing w/ the company.

What is still a bit murky to me is when IPIX will sign a partnership for B-OM and if they are ready to announce same prior to submitting and receiving an OK for the P3 from both the FDA and EMA. Hope BP is ready to sign deal as soon as we get positive news we can proceed w/ P3 in both USA and Europe and we can announce a substantial upfront payment to be able to get some cash in our coffers.

As to IBD, I have no clue if that is actively being discussed now or if a partnership for that is predicated on successful pill formulation.

Regarding another bridge financing play and dilution to put us in a better position for IBD deal, if it has to be it has to be. Most of us can pick up shares now at low, low prices to make up for the dilution so that mitigates the payback expectations for many due to the further dilution.

I don't expect any news this week, except for possible further financing deal filing. I can live with another few weeks for EMA to get it all together as everything seems to be on a good track and with some cash we can again get hitting on all cylinders with further efforts (if enough cash) to pill formulations for B and K, topical creams for B dermatology indications, and a final end to further dilution to keep the doors open.

Price may get whacked for another couple of weeks, but the end game will make it all worthwhile IMO. Many think we are really sucking wind but the tale of the tape shows the real desperation at this time is on the side of those betting against the company.

These are all my WAGs as to upcoming events, no basis in fact or anything I have heard recently. Overall, though, those I talk to are all on the same page and that is the page loaded with confidence in the future of IPIX.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 297

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Breast Aesthetics: Embracing Natural Beauty

Updated Category News Views 467

Global Surgeons Advocate for Natural Breast Aesthetics In a groundbreaking initiative, a coalition of prominent plastic surgeons has introduced a new standard for breast augmentation emphasizing 'Natural Breast Beauty'. This initiative, presented at an international symposium in Milan, arose from increasing concerns regarding aesthetically unpleasing results and the...

Continue Reading
Pony AI Receives Strong Buy Ratings from Top Financial Firms

Updated Category News Views 189

Pony AI's Promising Future with Top Ratings Pony AI has recently come into the spotlight after receiving a positive assessment from two major financial institutions, Bank of America and Goldman Sachs. Both firms have initiated coverage on the company, marking it with a favorable ‘buy’ rating. Bank of America has set an ambitious price target of $18, indicating a...

Continue Reading
Rapport Therapeutics: Insights on Neuropsychiatry Conference Participation

Updated Category News Views 116

Rapport Therapeutics at the Neuropsychiatry Summit BOSTON and SAN DIEGO – Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biotechnology company, is making headway in the realm of neurological and psychiatric disorders through its small molecule precision medicines. The company is gearing up to participate in the upcoming TD Cowen's 5th Annual Novel...

Continue Reading
Innovative Credit Card Security Solution by InventHelp Inventor

Updated Category News Views 228

Innovative Credit Card Security Solution An inventor has come up with a groundbreaking idea to guard credit and debit card users against unauthorized transactions. This invention, termed the CREDIT CARD SECURITY LOCK, aims to provide an extra layer of protection, ensuring that only the legitimate cardholder can access their funds. Revolutionizing Payment Security This...

Continue Reading
Polling Insights: Vance and Walz's Debate Performance Analyzed

Updated Category News Views 87

Debate Highlights Between Vance and Walz In a recent debate that captured public attention, Minnesota Governor Tim Walz and Senator J.D. Vance (R-Ohio) engaged in a spirited discussion that left many viewers with strong opinions. According to flash polls conducted by CNN, Vance emerged slightly ahead in the eyes of debate watchers. Polling Results Breakdown The debate was...

Continue Reading